| External factors: | Doxorubicin |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Cancer |
| Experiment: | SA-β-gal activity assay//BrdU assay//Cell morphological analysis |
| Description: | Doxorubicin induced a flat, senescence-like cell morphology, increased senescence-associated β-galactosidase (SA-β-gal)-positive cells to approximately 80%, and blunted BrdU incorporation into the DNA of proliferating cells by > 95% ;IFN-γ + TNF also induced the flat senescence-associated morphology,increased SA-β-gal activity. |
| Target gene: | AGO2 |
| R-EF-Target gene: | -- |
| Official symbol(s): | AGO2 |
| Target gene experiment: | Western blot//Immunostaining//qPCR |
| Target gene description: | Ago2 translocation could also be demonstrated by western blot analysis of nuclear extracts of doxorubicin-treated MCF-7 cells；Cytokine-induced translocation of Ago2 into the nucleus of MCF-7 cells was verified by western blot analysis of nuclear extracts. A204 rhabdomyosarcoma (blue dots) or MCF-7 breast cancer cells (red dots) confirmed the downregulation of all five cell cycle genes which are known to be regulated by Ago2. after 24 h and 48 h. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: